99 filings
Page 3 of 5
8-K
0x6k so218b5q1girw
9 Mar 23
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
9:00am
8-K
vz4f2don5wz4504
22 Feb 23
Entry into a Material Definitive Agreement
6:06am
DEF 14C
056nmio pr7ld16
13 Feb 23
Information statement
5:06pm
8-K
es7qaicog
6 Feb 23
Regulation FD Disclosure
5:35pm
PRE 14C
frbaxzb l4eyn7
2 Feb 23
Preliminary information
4:10pm
EFFECT
1f7uytt5
2 Feb 23
Notice of effectiveness
12:15am
424B3
tad6v3
1 Feb 23
Prospectus supplement
4:30pm
CORRESP
wqynq
30 Jan 23
Correspondence with SEC
12:00am
UPLOAD
j7l1uc5 wvb
27 Jan 23
Letter from SEC
12:00am
CORRESP
wibjp6owvgfb
27 Jan 23
Correspondence with SEC
12:00am
8-K
3jnjehfp
26 Jan 23
Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31
4:15pm
CORRESP
hmvjd34vwk qnqonf
25 Jan 23
Correspondence with SEC
12:00am
D
qkclfs0mu 4z
20 Jan 23
$4.00 mm in securities to be acquired, sold $4.00 mm, 1 investor
4:24pm
8-K
h9u6pqniilm qecq
12 Jan 23
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
4:59pm
8-K
veqteu502 l460f
19 Dec 22
Submission of Matters to a Vote of Security Holders
3:30pm
S-8
c45kik5rlfvhb ziemb
12 Dec 22
Registration of securities for employees
4:23pm
8-K
q0lchq qg
7 Dec 22
Regulation FD Disclosure
4:10pm
DEF 14A
r7pxepehss9g8t
21 Nov 22
Definitive proxy
5:28pm